US 12,168,676 B2
Microbially derived peptides and proteins for immunotherapy
Yuliya Katlinskaya, Brisbane, CA (US); Helena Kiefel, Brisbane, CA (US); Kareem L. Graham, Brisbane, CA (US); Todd Z. DeSantis, Brisbane, CA (US); Sunit Jain, Brisbane, CA (US); Andrew W. Han, Brisbane, CA (US); and Karim Dabbagh, Brisbane, CA (US)
Assigned to Genevive, Inc., San Mateo, CA (US)
Appl. No. 17/420,813
Filed by Genevive, Inc., San Mateo, CA (US)
PCT Filed Jan. 6, 2020, PCT No. PCT/US2020/012431
§ 371(c)(1), (2) Date Jul. 6, 2021,
PCT Pub. No. WO2020/142786, PCT Pub. Date Jul. 9, 2020.
Claims priority of provisional application 62/788,950, filed on Jan. 6, 2019.
Prior Publication US 2022/0089653 A1, Mar. 24, 2022
Int. Cl. C07K 14/195 (2006.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01)
CPC C07K 14/195 (2013.01) [A61P 35/00 (2018.01); A61P 37/04 (2018.01); A61K 38/00 (2013.01)] 10 Claims
 
1. A method for treating a disease in a subject in need thereof, comprising:
administering to the subject a pharmaceutical composition, comprising:
i. a therapeutic peptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:1; and
ii. a pharmaceutically acceptable carrier.